Tislelizumab demonstrates non-inferior OS compared to sorafenib for treating hepatocellular carcinoma

Abemaciclib plus trastuzumab fulvestrant increased OS for HR+, HER2+ advanced breast cancer

Cancer survivors' stories: An African perspective

ESMO 2022: Breast and ovarian trial analysis

ERMES study suggests a strategy of de-escalation with only cetuximab in first line therapy for RAS and BRAF wild type mCRC

Neoadjuvant immunotherapy improves outlook in high-risk melanoma

Potential for enfortumab vedotin plus pembrolizumab in cisplatin-ineligible locally advanced or metastatic urothelial cancer

Pembrolizumab/carboplatin/paclitaxel combo shows antitumour activity in first-line recurrent/metastatic HNSCC

ESMO 2022: Highlights, commentary and analysis

Ideal duration of androgen deprivation therapy with post-operative radiotherapy for prostate cancer

Sotorasib shows superior PFS and ORR compared to docetaxel for NSCLC

ESMO 2022: Renal roundup